FDA Grants Ceritinib Priority Review in Frontline ALK+ NSCLC

February 23rd, 2017 – The FDA has granted a priority review to ceritinib as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC), according to Novartis, the manufacturer of the second-generation ALK inhibitor. The priority review is based on findings from the phase III ASCEND-4 trial, in which ceritinib reduced the risk of disease progression or death by 45% compared with standard chemotherapy. The median … (leggi tutto)